Condition: Gastrointestinal Stromal Tumors · Sponsor: Ono Pharmaceutical Co., Ltd.
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
This description comes directly from the study's public registry record.
North America Clinical Trial Support Desk · +18665877745 (Toll-Free) · clinical_trial@ono-pharma.com
International Clinical Trial Support Desk · +17162141777 (Standard) · clinical_trial@ono-pharma.com
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| National Cancer Center Hospital | Tokyo, Chuo-ku, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07618377